Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.91)
# 254
Out of 5,134 analysts
700
Total ratings
52.2%
Success rate
22.1%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics | Maintained: Buy | $25 → $20 | $1.90 | +952.63% | 4 | Nov 12, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $137 → $167 | $94.61 | +76.51% | 34 | Nov 4, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $160 → $166 | $112.16 | +48.00% | 23 | Nov 4, 2026 | |
| DBVT DBV Technologies | Reiterated: Buy | $55 → $47 | $11.88 | +295.62% | 46 | Oct 29, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $12 → $27 | $11.41 | +136.63% | 22 | Oct 1, 2026 | |
| IRLA IRulya Therapeutics | Upgraded: Buy | $77 | $38.33 | +100.89% | 1 | Sep 22, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $74 → $79 | $34.18 | +131.13% | 35 | Sep 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $165 → $170 | $134.86 | +26.06% | 38 | Aug 31, 2026 | |
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $3.70 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $113 → $110 | $20.95 | +425.06% | 26 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $7 | $0.6109 | +1,045.85% | 2 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $3 | $4.19 | -28.40% | 1 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $745 → $739 | $433.03 | +70.66% | 62 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $11 | $1.93 | +469.95% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 → $150 | $46.20 | +224.68% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $11 | $4.31 | +155.22% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 → $86 | $57.72 | +49.00% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $7.65 | +266.01% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.26 | +534.92% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.66 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $11 | $4.99 | n/a | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $2.73 | n/a | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 → $32 | $0.919 | n/a | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $7.61 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $15.80 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $31.85 | n/a | 1 | May 12, 2023 |
Kalaris Therapeutics
Nov 12, 2026
Maintained: Buy
Price Target: $25 → $20
Current: $1.90
Upside: +952.63%
Mirum Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $137 → $167
Current: $94.61
Upside: +76.51%
Rhythm Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $160 → $166
Current: $112.16
Upside: +48.00%
DBV Technologies
Oct 29, 2026
Reiterated: Buy
Price Target: $55 → $47
Current: $11.88
Upside: +295.62%
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $12 → $27
Current: $11.41
Upside: +136.63%
IRulya Therapeutics
Sep 22, 2026
Upgraded: Buy
Price Target: $77
Current: $38.33
Upside: +100.89%
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $74 → $79
Current: $34.18
Upside: +131.13%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $165 → $170
Current: $134.86
Upside: +26.06%
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.70
Upside: -
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $113 → $110
Current: $20.95
Upside: +425.06%
Aug 6, 2026
Reiterated: Buy
Price Target: $9 → $7
Current: $0.6109
Upside: +1,045.85%
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $4.19
Upside: -28.40%
Jul 17, 2026
Reiterated: Buy
Price Target: $745 → $739
Current: $433.03
Upside: +70.66%
May 14, 2026
Reiterated: Buy
Price Target: $14 → $11
Current: $1.93
Upside: +469.95%
May 14, 2026
Reiterated: Buy
Price Target: $170 → $150
Current: $46.20
Upside: +224.68%
May 13, 2026
Reiterated: Buy
Price Target: $12 → $11
Current: $4.31
Upside: +155.22%
May 12, 2026
Reiterated: Buy
Price Target: $61 → $86
Current: $57.72
Upside: +49.00%
May 7, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $7.65
Upside: +266.01%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.26
Upside: +534.92%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.66
Upside: -
Oct 23, 2025
Reiterated: Buy
Price Target: $8 → $11
Current: $4.99
Upside: n/a
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $2.73
Upside: n/a
Oct 6, 2025
Reiterated: Buy
Price Target: $120 → $32
Current: $0.919
Upside: n/a
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $7.61
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $15.80
Upside: n/a
May 12, 2023
Reiterated: Buy
Price Target: $24
Current: $31.85
Upside: n/a